Buy & Sell Northrop Grumman Corporation (NOC) – Northrop Grumman Corporation Price Today
Aura AI Summary
Key Stats
- $80.06BMarket Cap
- IndustrialsSector
- -29.6%3M Drawdown
- $94.29BEnterprise Value
- 1.67%Dividend Yield
- 65 daysTypical Hold Time
Northrop Grumman Corporation (NOC) is currently valued at a market capitalization of $80.06B, with an enterprise value of $94.29B. Over the past 52 weeks, Northrop Grumman Corporation has traded between a low of $483.38 and a high of $768.02, highlighting its annual price range. Over the past three months, Northrop Grumman Corporation has recorded a drawdown of -29.6%, reflecting recent price volatility. Northrop Grumman Corporation offers a dividend yield of 1.67%, with the most recent dividend of $2.47 paid on 01 Jun 26. On average, investors hold Northrop Grumman Corporation for approximately 65 days, indicating typical investor behavior on the platform.
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Most Recent News
US closes loophole allowing Nvidia, AMD AI chip exports to Chinese firms abroad
The US Department of Commerce has closed a loophole that allowed advanced AI chips from Nvidia and AMD to be exported to Chinese companies operating outside China, such as in Malaysia. This move strengthens US efforts to restrict China's access to cr...

Ascentage Pharma shows promising results for olverembatinib combo in tough leukemia cases at ASCO 2026
Ascentage Pharma presented positive Phase Ib trial results at ASCO 2026 for olverembatinib combined with blinatumomab in patients with relapsed or refractory Philadelphia chromosome-positive leukemias, showing high response rates and manageable safet...

Ascentage Pharma shows promising early results for alrizomadlin in pediatric solid tumors at ASCO 2026.
Ascentage Pharma presented initial clinical data for alrizomadlin (APG-115), an MDM2-p53 inhibitor, in pediatric patients with relapsed or metastatic solid tumors at ASCO 2026. The drug, tested alone or with lisaftoclax, showed preliminary anti-tumor...
